New antipsychotics a review of their current status and clinical potential

CNS Drugs

Volumn 6, Issue 1, 1996, Pages 71-82

  Kerwin, Robert ^a   Taylor, David ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; REMOXIPRIDE; RISPERIDONE; SERTINDOLE; ZIPRASIDONE;

CONSTIPATION; HEADACHE; HUMAN; PRIORITY JOURNAL; REVIEW; SCHIZOPHRENIA; SOMNOLENCE; VERTIGO;

EID: 0029902047     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199606010-00006     Document Type: Review

References (62)

1. Reynolds GP. Developments in the drug treatment of schizophrenia. Trends Neurosci 1992; 13: 116-21
2. Creese I, Burt DR, Snyder SH. Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976; 192: 481-3
3. Sanberg PR. Haloperidol-induced catalepsy is mediated by post-synaptic dopamine receptors. Nature 1980; 284: 472-3
4. 2 dopamine receptor blockade hypothesis of schizophrenia. Lancet 1992; 340: 199-202
5. 2 blocker. Drug Dev Res 1986; 8: 205-11
6. 3 receptors. Mol Pharmacol 1993; 43: 749-54
7. Kelly PH, Seviour PW, Iversen SD. Amphetamine and apomorphine responses in the rat following 6-0HDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res 1975; 94: 507-22
8. Gerlach J. New antipsychotics: classification, efficacy and adverse effects. Schizophr Bull 1991; 17: 289-309
9. Nutt DJ. Specific anatomy, non specific drugs: the present state of schizophrenia. J Psychopharmacol 1990; 4: 171-5
10. Meltzer HY. Pre-clinical pharmacology of atypical antipsychotics drugs: a selective review. Br J Psychiatry 1996; 168 Suppl. 129: 23-31
11. 3H-spiperone binding in the rat brain: relation to blockade of apomorphine-induced hyperactivity and stereotypes. J Neurol Transm 1981; 52: 163-73
12. 2 receptor occupancy in patients treated with classical neuroleptics and clozapine: relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-44
13. 125I-IBZM single photon emission tomography (SPET) study. Psychopharmacology 1995; 117: 55-61
14. 123I-IBZM single photon emission tomography (SPET) study. Psychopharmacology. In press
15. 11C-raclopride. Psychopharmacology 1993; 112: 308-14
16. Moore NA, O'Calligaro DO, Wong DT, et al. The pharmacology of olanzapine and other new antipsychotic agents. Curr Opin Invest Drug 1993; 2: 281-93
17. Goldstein JM, Arvanitis LA. ICI 204,636 (Seroquel™): a dibenzothiazepine atypical antipsychotic. Review of preclinical pharmacology and highlights of phase II clinical trials. CNS Drug Reviews 1995; 1 (1): 50-73
18. Hyttel J, Aint J, Costall B, et al. Pharmacological profile of the atypical neuroleptic, sertindole. Clin Neuropharmacol 1992; 15 Suppl. 1: 267a-8a
19. Seeger TF, Seymour PA, Schmidt AW, et al. Ziprasidone (CP-88,059) a new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exper Ther. In press
20. Imperato A, Angelucci L. Effects of the atypical neuroleptics clozapine and fluperlapine on the in vivo dopamine release in the dorsal striatum and in the prefrontal cortex [abstract]. Psychopharmacology 1988; 45: 786-9
21. 4 receptor with high affinity for the antipsychotic clozapine. Nature 1991; 350: 610-9
22. 4 receptors elevated in schizophrenia. Nature 1993; 365: 441-4
23. 4 receptors increased in schizophrenia? J Neurochem 1994; 63: 1576-7
24. 4 receptor subtypes and response to clozapine. Lancet 1993; 341: 116
25. 2 receptors: an autoradiographic analysis in rat brain. Brain Res Bull 1986; 16: 517-25
26. 2 receptors in the medial prefrontal cortex: microiontophoric studies. Brain Res 1990; 506: 346-8
27. 2 receptor occupancy in clozapine treated patients demonstrated by PET. Psychopharmacology 1993; 110: 365-7
28. 2a receptor gene. Lancet 1996; 346: 81-2
29. 2c receptor gene. Neuroreport. In press
30. Graybiel AM, Moratalla R, Robertson HA. Amphetamine and cocaine induced drug specific activation of the c-fos gene in striosome-matrix compartments and limbic subdivision of the striatum. Proc Natl Acad Sci USA 1990; 87: 6912-6
31. 2 antagonistic properties. J Pharmacol Exp Ther 1988; 244: 655-93
32. Jannssen Research Foundation. Risperidone: investigators' brochure. 1990
33. Schotte A, De Bruyckere K, Jannssen PFM. Receptor occupancy by ritanserin and risperidone measured using ex vivo antoradiography. Brain Res 1989; 506: 295-301
34. Lessen JE, Gommeron WE, Eens A, et al. The biochemical profile of risperidone. J Pharmacol Exp Ther 1992; 24: 661-70
35. Kerwin RW. The new atypical antipsychotics: a lack of extrapyramidal side effects and new routes in schizophrenia research. Br J Psychiatry 1994; 164: 141-8
36. 2 neurotransmission as revealed by selective antagonism of hyperactivity to truptamine and apomorphic. J Pharmacol Exp Ther 1990; 254: 945-51
37. Moore NA, Tye NC, Axton MS. The behavioural pharmacology of olanzapine - a novel atypical antipsychotic. J Pharmacol Exper Ther 1992; 262: 545-51
38. Seroquel: a putative atypical antipsychotic drug with serotonin-and dopamine- receptor antagonist properties. J Clin Psychiatry 1995; 56 (9): 438-45
39. Migler BM, Warawa EJ, Malick JB. Seroquel: behavioural effects in conventional and novel tests for atypical antipsychotic drugs. Psychopharmacology 1993; 112: 299-307
40. Zorn SH, Seeger TF, Seymour PH, et al. Ziprasidone (CP.88.059): preclinical pharmacology review. Jpn Neuropsychopharmacol. In press
41. Arnt J. Pharmacological speculation of conditional avoidance response inhibition in rats: inhibition by neuroleptics and correlation to dopamine receptor blockade. Acta Pharmacol Toxicol (Copenh) 1982; 51: 321-9
42. Saller CF, Salamer AI. Seroquel: biochemical profile of a potential antipsychotic. Psychopharmacology 1993; 112: 285-92
43. Goldstein JM, Litwin LC, Sutton EB. Seroquel: electrophysiological profile of a potential antipsychotic. Psychopharmacology 1993; 112: 293-8
44. Sanchez C, Arnt J, Dragsted N, et al. Neurochemical and in vivo pharmacological profile of sertindole, a limbic selective neuroleptic compound. Drug Dev Res 1991; 22: 239-50
45. Skarsfeldt T, Perregaard J. Sertindole, a new neuroleptic with extreme selectivity on A10 versus A9 dopamine neurones in the rat. Eur J Pharmacol 1990; 182: 613-4
46. Harrison DA, Satterlee W, Tran P, et al. Olanzapine: a potential atypical antipsychotic agent. Phase II clinical findings. Schizophr Res 1994 Jan; 11 (2): 107-8
47. Williamson DJ, Tran PV, Beasley CM, et al. Additional clinical experience with olanzapine, an 'atypical' antipsychotic Basingstoke, England: Eli Lilly and Co., 1995. (Data on file)
48. Tran PV, Beasley CM, Tollefson GD. Clinical efficacy and safety of increasing doses of olanzapine: a new atypical antipsychotic. Basingstoke, England: Eli Lilly and Co., 1995. (Data on file)
49. Wood AJ, Beasley CM, Tollefson GD, et al. Efficacy of olanzapine on the positive and negative symptoms of schizophrenia [abstract]. Eur Neuropsychopharmacol 1994 Sep; 4 (3): 224-5
50. Wolters ECh. Olanzapine in the treatment of dopaminomimetic psychosis [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 (3): 348
51. Data on file. Eli Lilly and Co., Basingstoke, England
52. Fabre LF, Arvanitis L, Pultz J, et al. ICM 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia. Clin Ther 1995; 17 (3): 366-78
53. Link C, Arvanitis L, Miller B, et al. A multicentre, placebo-controlled, double-blind evaluation of Seroquel™ in hospitalised patients with acute exacerbation of chronic and subchronic schizophrenia [abstract]. Eur Neuropsychopharmacol 1994 Sep; 4 (3): 385-6
54. Link C, Smith A, Miller B, et al. A multicentre, double-blind, controlled comparison of Seroquel™ and chlorpromazine in the treatment of hospitalised patients with acute exacerbation of subchronic and chronic schizophrenia [abstract]. Eur Neuropsychopharmacol 1994 Sep; 4 (3): 385
55. Hirsch S, Arvanitis L, Miller B, et al. A multicentre, double-blind, placebo-controlled comparison of low and high dosage regimens of Seroquel™ in the treatment of hospitalised patients with acute exacerbation of subchronic or chronic schizophrenia [abstract]. Eur Neuropsychopharmacol 1994 Sep; 4 (3): 384-5
56. Hirsch SR, Link CCG, Goldstein JM, et al. ICI 204,636: a new atypical antipsychotic drug. Br J Psychiaty 1996; 168 Suppl. 29: 45-56
57. Daniel D, Staser J, Schmitz P, et al. Two open label, long term studies of sertindole [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 (3): 348
58. Targum S, Zborowski M, Henry M, et al. Efficacy and safety of sertindole in two double-blind, placebo-controlled trials of schizophrenic patients [abstract]. Eur Neuropsychopharmacol 1995 Sep; 5 (3): 348-9
59. Dunn JD, Fitton A, Sertindole. CNS Drugs 1996; 5: 224-30
60. Data on file. Lundbeck A/S, Copenhagen, Denmark
61. O'Connor R, Harrigan E, Heym J, et al. The efficacy and safety profile of a new antipsychotic, ziprasidone. Poster at the VIIIth Congress of the European College of Neuropsychopharmacology: 1995 Sep 30-Oct 4: Venice, Italy
62. Bradbury JE, Zorn SH, Wilner K, et al. The preclinical profile of the new antipsychotic, ziprasidone. Poster at the VIIIth Congress of the European College of Neuropsychopharmacology: 1995 Sep 30-Oct 4: Venice, Italy